The treatment of severe hepatitis B virus reactivation after chemotherapy

Nature Reviews Clinical Oncology

Volumn 9, Issue 6, 2012, Pages 350-

  Li, Xing ^a   Xing, Yan Fang ^b   Lin, Qu ^a   Dong, Min ^a   Wan, Xiang Bo ^a   Wu, Xiang Yuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

ACUTE LIVER FAILURE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; HEPATITIS B; HEPATITIS C; HUMAN; LETTER; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; VIRUS REACTIVATION;

HEPATITIS B; HEPATITIS C; HUMANS; NEOPLASMS;

EID: 84861721928     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.1-c1     Document Type: Letter

References (9)

1. Torres, H. A. & Davila, M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat. Rev. Clin. Oncol. 9, 156-166 (2012).
2. Li, X. et al. Prognostic analysis of acute exacerbations of hepatitis B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk. Lymphoma 51, 1678-1685 (2010).
3. Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22, 1170-1180 (2011).
4. Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology 45, 507-539 (2007). (Pubitemid 46374607)
5. Yeo, W. & Johnson, P. J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43, 209-220 (2006).
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009).
7. Lee, W. M., Squires, R. H. Jr., Nyberg, S. L., Doo, E. & Hoofnagle, J. H. Acute liver failure: summary of a workshop. Hepatology 47, 1401-1415 (2008). (Pubitemid 351547926)
8. Tillmann, H. L. et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J. Viral Hepat. 13, 256-263 (2006).
9. Mori, N. et al. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J. Gastroenterol. http://dx.doi.org/ 10.1007/s00535-012-0561-8